Identifying bronchoconstriction from the ratio of diaphragm EMG to tidal volume.
Adolescent
Adult
Aged
Asthma
/ diagnosis
Bronchial Hyperreactivity
/ diagnosis
Bronchoconstriction
/ drug effects
Bronchodilator Agents
/ administration & dosage
Diaphragm
/ physiopathology
Electromyography
Female
Histamine
/ administration & dosage
Humans
Male
Middle Aged
Tidal Volume
/ physiology
Young Adult
Asthma
Bronchial challenge test
Bronchodilator test
Diaphragm EMG
Journal
Respiratory physiology & neurobiology
ISSN: 1878-1519
Titre abrégé: Respir Physiol Neurobiol
Pays: Netherlands
ID NLM: 101140022
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
28
12
2020
revised:
09
05
2021
accepted:
16
05
2021
pubmed:
22
5
2021
medline:
21
1
2022
entrez:
21
5
2021
Statut:
ppublish
Résumé
A fall of ≥ 20 % in forced expiratory volume in the first second (FEV1) with a cumulative dose of histamine ≤ 7.8 μmol is considered to indicate bronchial hyperactivity, but no method exists for patients who cannot perform spirometry properly. Here we hypothesized that increases in respiratory central output measured by chest wall electromyography of the diaphragm (EMGdi-c) expressed as a function of tidal volume (EMGdi-c/VT) would have discriminative power to detect a 'positive' challenge test. In a physiological study EMGdi was recorded from esophageal electrode (EMGdi-e) in 16 asthma patients and 16 healthy subjects during a histamine challenge test. In a second study, EMGdi from chest wall surface electrodes (EMGdi-c) was measured during a histamine challenge in 44 asthma patients and 51 healthy subjects. VT was recorded from a digital flowmeter during both studies. With histamine challenge test the change in EMGdi-e/VT in patients with asthma was significantly higher than that in healthy subjects (104.2 % ± 48.6 % vs 0.03 % ± 17.1 %, p < 0.001). Similarly there was a significant difference in the change of EMGdi-c/VT between patients with asthma and healthy subjects (90.5 % ± 75.5 % vs 2.4 % ± 21.7 %, p < 0.001). At the optimal cut-off point (29 % increase in EMGdi-c/VT), the area under the ROC curve (AUC) for detection of a positive test was 0.91 (p < 0.001) with sensitivity 86 % and specificity 92 %. We conclude that EMGdi-c/VT may be used as an alternative for the assessment of bronchial hypersensitivity and airway reversibility to differentiate patients with asthma from healthy subjects.
Sections du résumé
BACKGROUND
A fall of ≥ 20 % in forced expiratory volume in the first second (FEV1) with a cumulative dose of histamine ≤ 7.8 μmol is considered to indicate bronchial hyperactivity, but no method exists for patients who cannot perform spirometry properly. Here we hypothesized that increases in respiratory central output measured by chest wall electromyography of the diaphragm (EMGdi-c) expressed as a function of tidal volume (EMGdi-c/VT) would have discriminative power to detect a 'positive' challenge test.
METHODS
In a physiological study EMGdi was recorded from esophageal electrode (EMGdi-e) in 16 asthma patients and 16 healthy subjects during a histamine challenge test. In a second study, EMGdi from chest wall surface electrodes (EMGdi-c) was measured during a histamine challenge in 44 asthma patients and 51 healthy subjects. VT was recorded from a digital flowmeter during both studies.
RESULTS
With histamine challenge test the change in EMGdi-e/VT in patients with asthma was significantly higher than that in healthy subjects (104.2 % ± 48.6 % vs 0.03 % ± 17.1 %, p < 0.001). Similarly there was a significant difference in the change of EMGdi-c/VT between patients with asthma and healthy subjects (90.5 % ± 75.5 % vs 2.4 % ± 21.7 %, p < 0.001). At the optimal cut-off point (29 % increase in EMGdi-c/VT), the area under the ROC curve (AUC) for detection of a positive test was 0.91 (p < 0.001) with sensitivity 86 % and specificity 92 %.
CONCLUSIONS
We conclude that EMGdi-c/VT may be used as an alternative for the assessment of bronchial hypersensitivity and airway reversibility to differentiate patients with asthma from healthy subjects.
Identifiants
pubmed: 34020067
pii: S1569-9048(21)00077-X
doi: 10.1016/j.resp.2021.103692
pii:
doi:
Substances chimiques
Bronchodilator Agents
0
Histamine
820484N8I3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103692Informations de copyright
Copyright © 2021. Published by Elsevier B.V.